Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrigAMI-5: Amivantamab + Carboplatin + Pembrolizumab vs Standard Platinum + Pembrolizumab + 5-FU in R/M HNSCC
jRCT2011250045Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall Survival and Objective Response Rate (BICR, RECIST v1.1). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2011250045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250045.